US-based Banner Sun Health Research Institute and Banner Alzheimer’s Institute have initiated the clinical trial of the NeuroEM 1000 wearable head device to treat patients with Alzheimer’s Disease.
Developed by NeuroEM Therapeutics, the device is based on the company’s transcranial electromagnetic treatment (TEMT) to treat the entire brain.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
TEMT breaks down the small protein aggregates (amyloid oligomers) found inside brain cells that are considered responsible for Alzheimer’s development in the brain.
TEMT then triggers an increased low-energy production of Alzheimer’s-diseased brain cells by enhancing their mitochondrial function since mitochondrial dysfunction is an early and critical symptom paving the development of the disease.
The technology is similar to the electromagnetic waves emitted by cell phones, exposure to which has been proven to facilitate beneficial cognitive changes to the EEG, increases brain energy production, and has no severe effects on health for a longer period of time.
NeuroEM Therapeutics president and CEO and developer of TEMT technology Dr Gary Arendash said: “We are very pleased to have two of the country’s most notable and trusted Alzheimer’s research institutes performing this first-of-its-kind clinical trial.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Although the Phase I trial is primarily to investigate safety of the TEMT head device, a number of measures have been included in the trial’s design that could provide evidence of therapeutic efficacy.”
TEMT involves interdigitated electric and magnetic waves that can easily make its way through the entire human brain to address the disease.
During the clinical trial, patients with AD will be treated with the NeuroEM 1000 head device at home which will be worn twice daily for one-hour treatments.
The treatment at home will not restrict normal mobility of the patient.
The trial is expected to be completed next year.
